All In Biotech

Drug Trial Radar · NCT07903506

To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

A Phase 3, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant Following Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction in Participants With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Mar 2039

Study completion Mar 2042

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM). The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel administered after quadruplet-based induction versus standard of care therapy (SOCT; quadruplet-based induction followed by autologous stem cell transplant (auto-SCT) in participants with NDMM who are eligible for auto-SCT.

Conditions

  • Newly Diagnosed Multiple Myeloma

Interventions

  • Anitocabtagene AutoleucelDrug

    A single infusion of CAR+ transduced autologous T cells

  • IsatuximabDrug

    Administered subcutaneously (SC)

  • BortezomibDrug

    Administered SC

  • LenalidomideDrug

    Administered orally (PO)

  • DexamethasoneDrug

    Administered orally (PO)

  • FludarabineDrug

    Administered IV

  • CyclophosphamideDrug

    Administered IV

  • MelphalanDrug

    Administered intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 MonthsTime frame: Up to 12 months
  2. Progression-Free Survival (PFS)Time frame: Up to 15 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.